

QOPI® CERTIFICATION TRACK 2019 MEASURE SUMMARY

MODULE	MEASURE	MEASURE	NQF Endorsed Measure
CORE	1	Pathology report confirming malignancy*	
CORE	2	Staging documented within one month of first office visit*	NQF Endorsed #0386 (adapted)
CORE	6	Pain addressed appropriately (defect-free measure 3, 4a, and 5) *	NQF Endorsed #0383 (adapted)
CORE	6a	Pain assessed on either of the two most recent office visits*	NQF Endorsed #0383/#0384 (adapted)
CORE	9	Documented plan for chemotherapy, including doses, route, and time intervals*	
CORE	10	Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration*	
CORE	11	Chemotherapy intent discussion with patient documented*	
CORE	13oc4a	Documented plan for oral chemotherapy: Dose*	
CORE	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration) *	
CORE	16	Patient consent for chemotherapy (combined measure 14 or 15) *	
CORE	21aa	Smoking status/tobacco use documented in past year*	NQF Endorsed #0028 (adapted)
CORE	24	Patient emotional well-being assessed by the second office visit*	
CORE	25	Action taken to address problems with emotional well-being by the second office visit*	
CORE	25b	Height, Weight, and BSA documented prior to chemotherapy*	
SMT	27	Corticosteroids and serotonin antagonist prescribed or administered with moderate/high emetic risk chemotherapy*	
SMT	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age*	
BR	53	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer*	NQF Endorsed #0559 (adapted)
BR	54	Test for Her-2/neu overexpression or gene amplification*	NQF Endorsed #1878 (adapted)
BR	59	Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA (T1c) and IB - III ER or PR positive breast cancer*	NQF Endorsed #0220/#0387 (adapted)

Top 5 Test Measures and Top 5 Measures = American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology Lowell E. JCO May 10, 2012:1715-1724.

QOPI® CERTIFICATION TRACK 2019 MEASURE SUMMARY

MODULE	MEASURE	MEASURE	NQF Endorsed Measure
CRC	66	CEA within 4 months of curative resection for colorectal cancer*	
CRC	68	Adjuvant chemotherapy received within 2 months of diagnosis by patients with AJCC stage III colon cancer*	NQF Endorsed #0223/#0385 (adapted)
CRC	73	Colonoscopy before or within 6 months of curative colorectal resection or completion of primary adjuvant chemotherapy*	NQF Endorsed #1859 (adapted)
CRC	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy*	NQF Endorsed #1860 (adapted)
NSCLC	84	Performance status documented for patients with initial AJCC Stage IV or distant metastatic NSCLC*	
NSCLC	88	Patients with Stage IV NSCLC with a denocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy *	
GYNONC	94	Platin or taxane administered within 42 days following cytoreduction to women with invasive Stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer*	NQF Endorsed #0218

Top 5 Test Measures and Top 5 Measures = American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology Lowell E. JCO May 10, 2012:1715-1724.

Copyright© 2018 American Society of Clinical Oncology. All rights reserved. No part of this document may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission by the Society. Updated: 12/12/2018